Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) Gets New CMO

The management of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) appointed Dr. Lorianne Masuoka as Chief Medical Officer, effective March 2, 2015. Currently, Lou Vaickus, MD, was serving as an interim Chief Medical Officer. She is an experienced executive and also the President of renowned Life Sciences Consulting Firm, Akta Pharmaceutical Development LLC.

The profile

Dr. Masuoka has served on various senior management roles with top most companies in her working tenure. She was associated with Cubist Pharmaceuticals as Chief Medical Officer. The experience of working as CMO with other companies is an added advantage for Invivo Therapeutics. Along with Chief Medical Officer, she was also Senior VP with Cubist. Being a senior member of the management team, she was assigned with the responsibility of leading almost 150 employees. They were employed in different segments including clinical research division, clinical operations, data management, drug safety segment and biostatistics. The relevant experience of serving as CMO at Cubist will prove as a great asset during her services with Invivo.

Educational and career achievements

Dr. Masuoka not only brings experience of Cubist to Invivo, but also of working with other top companies like Nektar Therapeutics. She has worked on the profile of CMO and Senior VP with Nektar. She has spent almost two years with Nektar. Prior to it, she was working with FivePrime Therapeutics as VP, Clinical Development. She guided Oncology Department of Clinical Development at Chiron. She secured a medical qualification from the “University of California” and completed residency in neurology from university.


Expressing his views on the new appointment, Mark Perrin stated that Invivo is pleased to welcome Dr. Masuoka on board. She will play a significant role in transition period when the firm is focusing on an expedited timeline of the pilot study to take it ahead for a pivotal trial. Her experience as CMO with Cubist and Nektar will act as strong asset for the company.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.